Company intelligence / Profile preview
Neurophoenix
Franceneurophoenix.fr ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Neurophoenix has demonstrated preclinical proof-of-concept for its proprietary approach to neuron repair by inhibiting the PTEN pathway using viral peptide mimics. The company’s technology has shown stimulation of neurite outgrowth and potential for optic nerve regeneration in preclinical models, but no clinical results are yet available.
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Peptides/peptidomimetics (specifically, viral peptide mimics)Small molecules targeting PTEN pathway
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Neurophoenix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurophoenix.